Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design

The peptide hormone relaxin (RLX), also available as clinical-grade recombinant protein (serelaxin), holds great promise as a cardiovascular and anti-fibrotic agent but is limited by the pharmacokinetic issues common to all peptide drugs. In this study, by a computational modelling chemistry approac...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Ercole, Annunziata, Nistri, Silvia, Pacini, Lorenzo, Carotenuto, Alfonso, Santoro, Federica, Papini, Anna Maria, Bathgate, Ross A. D., Bani, Daniele, Rovero, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402926/
https://www.ncbi.nlm.nih.gov/pubmed/36034864
http://dx.doi.org/10.3389/fphar.2022.942178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402926/
https://www.ncbi.nlm.nih.gov/pubmed/36034864
http://dx.doi.org/10.3389/fphar.2022.942178

Ejemplares similares